相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania
Cristiana-Elena Vlad et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2022)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients
Francois-Pantaleon Musungayi Kajingulu et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2021)
Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis
Yimo Zhou et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study
Patricia Munoz Ramos et al.
METABOLITES (2021)
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Aureli Luquero et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort
Lorenz M. Pammer et al.
JOURNAL OF INTERNAL MEDICINE (2021)
The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
Nabil G. Seidah
JOURNAL OF LIPID RESEARCH (2021)
Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease
Laust Dupont Rasmussen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
Hyeon Seok Hwang et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes
Nutsiwat Didas et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2020)
Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome
Eduardo Molina-Jijon et al.
KIDNEY INTERNATIONAL (2020)
Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
Ferruh Artunc
KIDNEY INTERNATIONAL (2020)
Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis
Towe Stralberg et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2019)
PCSK9 inhibition and inflammation: A narrative review
Massimiliano Ruscica et al.
ATHEROSCLEROSIS (2019)
HDL in CKD-The Devil Is in the Detail
Florian Kronenberg
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population
Hui-Wen Zhang et al.
CARDIORENAL MEDICINE (2018)
PCSK9 in chronic kidney disease
P. Pavlakou et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2017)
Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism
Marion Morena et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients
Michele F. Eisenga et al.
DIABETES CARE (2017)
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia
Mary E. Haas et al.
CIRCULATION (2016)
PCSK9 in diabetic kidney disease
Usama Elewa et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2016)
PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
Kyrill S. Rogacev et al.
PLOS ONE (2016)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort
Stephanie Titze et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Lipid lowering with PCSK9 inhibitors
Razvan T. Dadu et al.
NATURE REVIEWS CARDIOLOGY (2014)
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Daniel Urban et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
The German Chronic Kidney Disease (GCKD) study: design and methods
Kai-Uwe Eckardt et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Lipoprotein metabolism and lipid management in chronic kidney disease
Bonnie C. H. Kwan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
分享论文
